Publications

Below you will find a list of all publications (co) written by members of HaemoScan. You can search Pubmed for more recent publications.

  1. The association of urinary epidermal growth factors with ADPKD disease severity and progression. Harskamp LR, Perez-Gomez MV, Heida JE, Engels GE, van Goor H, van den Heuvel MC, Streets AJ, Ong ACM, Ortiz A, Gansevoort RT; DIPAK Consortium. Nephrol Dial Transplant. 2023 Sep 29;38(10):2266-2275.

  2. The short-term effects of RBC transfusions on intestinal injury in preterm infants. Kalteren WS, Bos AF, Bergman KA, van Oeveren W, Hulscher JBF, Kooi EMW. Pediatr Res. 2023 Apr;93(5):1307-1313.

  3. Neonatal anemia relates to intestinal injury in preterm infants. Kalteren WS, Bos AF, van Oeveren W, Hulscher JBF, Kooi EMW. Pediatr Res. 2022 May;91(6):1452-1458.

  4. Does Intraoperative Cell Salvage Reduce Postoperative Infection Rates in Cardiac Surgery? van Klarenbosch J, van den Heuvel ER, van Oeveren W, de Vries AJ. J Cardiothorac Vasc Anesth. 2020 Jun;34(6):1457-1463.

  5. Development of an in vitro system and model-based translational framework to assess haemolysis risk following intravenous abuse of medications containing polyethylene oxide. Persich P, Engels GE, van Oeveren W, Galia E, Benay S, Thun S. Toxicol In Vitro. 2020 Jun;65:104776.

  6. Rapid Progression of Autosomal Dominant Polycystic Kidney Disease: Urinary Biomarkers as Predictors. Messchendorp AL, Meijer E, Visser FW, Engels GE, Kappert P, Losekoot M, Peters DJM, Gansevoort RT; on behalf of the DIPAK-1 study investigators. Am J Nephrol. 2019;50(5):375-385.

  7. The influence of gaseous microemboli on various biomarkers after minimized cardiopulmonary bypass. Stehouwer MC, de Vroege R, Bruggemans EF, Hofman FN, Molenaar MA, van Oeveren W, de Mol BA, Bruins P. Perfusion. 2020 Apr;35(3):202-208.

  8. Incidence of Massive Transfusion and Overall Transfusion Requirements During Lung Transplantation Over a 25-Year Period. Cernak V, Oude Lansink-Hartgring A, van den Heuvel ER, Verschuuren EAM, van der Bij W, Scheeren TWL, Engels GE, de Geus AF, Erasmus ME, de Vries AJ. J Cardiothorac Vasc Anesth. 2019 Sep;33(9):2478-2486.

  9. Stability of tubular damage markers epidermal growth factor and heparin-binding EGF-like growth factor in urine. Harskamp LR, Meijer E, van Goor H, Engels GE, Gansevoort RT. Clin Chem Lab Med. 2019 Sep 25;57(10):e265-e268.

  10. The optimal incubation time for in vitro hemocompatibility testing: Assessment using polymer reference materials under pulsatile flow with physiological wall shear stress conditions. Blok SLJ, van Oeveren W, Engels GE. J Biomed Mater Res B Appl Biomater. 2019 Oct;107(7):2335-2342.

  11. Additional filtering of blood from a cell salvage device is not likely to show important additional benefits in outcome in cardiac surgery. de Vries AJ, Vermeijden WJ, van Pelt LJ, van den Heuvel ER, van Oeveren W. Transfusion. 2019 Mar;59(3):989-994.

  12. Urinary Biomarkers to Identify Autosomal Dominant Polycystic Kidney Disease Patients With a High Likelihood of Disease Progression. Messchendorp AL, Meijer E, Boertien WE, Engels GE, Casteleijn NF, Spithoven EM, Losekoot M, Burgerhof JGM, Peters DJM, Gansevoort RT; DIPAK Consortium. Kidney Int Rep. 2017 Oct 14;3(2):291-301.

  13. Early biomarkers of brain injury and cerebral hypo- and hyperoxia in the SafeBoosC II trial. Plomgaard AM, Alderliesten T, Austin T, van Bel F, Benders M, Claris O, Dempsey E, Fumagalli M, Gluud C, Hagmann C, Hyttel-Sorensen S, Lemmers P, van Oeveren W, Pellicer A, Petersen TH, Pichler G, Winkel P, Greisen G. PLoS One. 2017 Mar 22;12(3):e0173440.

  14. Skin- and Plasmaautofluorescence in hemodialysis with glucose-free or glucose-containing dialysate. Ramsauer B, Engels GE, Graaff R, Sikole A, Arsov S, Stegmayr B. BMC Nephrol. 2017 Jan 5;18(1):5.

  15. Hemostatic action of polyurethane foam with 55% polyethylene glycol compared to collagen and gelatin. Broekema FI, van Oeveren W, Boerendonk A, Sharma PK, Bos RR. Biomed Mater Eng. 2016 Aug 12;27(2-3):149-59.

  16. Stirred, shaken, or stagnant: What goes on at the blood-biomaterial interface. Reviakine I, Jung F, Braune S, Brash JL, Latour R, Gorbet M, van Oeveren W. Blood Rev. 2017 Jan;31(1):11-21.

  17. In vitro blood flow model with physiological wall shear stress for hemocompatibility testing-An example of coronary stent testing. Engels GE, Blok SL, van Oeveren W. Biointerphases. 2016 Sep 18;11(3):031004.

  18. In vitro hemocompatibility testing: The importance of fresh blood. Blok SL, Engels GE, van Oeveren W. Biointerphases. 2016 Jun 12;11(2):029802.

  19. Intraoperative cell salvage during cardiac surgery is associated with reduced postoperative lung injury. Engels GE, van Klarenbosch J, Gu YJ, van Oeveren W, de Vries AJ. Interact Cardiovasc Thorac Surg. 2016 Mar;22(3):298-304.

  20. The SafeBoosC II randomized trial: treatment guided by near-infrared spectroscopy reduces cerebral hypoxia without changing early biomarkers of brain injury. Plomgaard AM, van Oeveren W, Petersen TH, Alderliesten T, Austin T, van Bel F, Benders M, Claris O, Dempsey E, Franz A, Fumagalli M, Gluud C, Hagmann C, Hyttel-Sorensen S, Lemmers P, Pellicer A, Pichler G, Winkel P, Greisen G. Pediatr Res. 2016 Apr;79(4):528-35.

  21. Tubular Injury Biomarkers to Detect Gentamicin-Induced Acute Kidney Injury in the Neonatal Intensive Care Unit. Jansen D, Peters E, Heemskerk S, Koster-Kamphuis L, Bouw MP, Roelofs HM, van Oeveren W, van Heijst AF, Pickkers P. Am J Perinatol. 2016 Jan;33(2):180-7.

  22. Urinary EGF Receptor Ligand Excretion in Patients with Autosomal Dominant Polycystic Kidney Disease and Response to Tolvaptan. Harskamp LR, Gansevoort RT, Boertien WE, van Oeveren W, Engels GE, van Goor H, Meijer E. Clin J Am Soc Nephrol. 2015 Oct 7;10(10):1749-56.

  23. Perioperative and bedside cerebral monitoring identifies cerebral injury after surgical correction of congenital aortic arch obstruction. Algra SO, Schouten AN, Jansen NJ, van Oeveren W, Haas F, Groenendaal F, Lemmers PM, van Haastert IC, Toet MC, de Vries LS. Intensive Care Med. 2015 Nov;41(11):2011-2.

  24. Elevated Urinary Connective Tissue Growth Factor in Diabetic Nephropathy Is Caused by Local Production and Tubular Dysfunction. Gerritsen KG, Leeuwis JW, Koeners MP, Bakker SJ, van Oeveren W, Aten J, Tarnow L, Rossing P, Wetzels JF, Joles JA, Kok RJ, Goldschmeding R, Nguyen TQ. J Diabetes Res. 2015;2015:539787.

  25. Biomarkers of lung injury in cardiothoracic surgery. Engels GE, van Oeveren W. Dis Markers. 2015;2015:472360.

  26. Corrigendum. The influence of body mass index on the accumulation of advanced glycation end products in hemodialysis patients. Arsov S, Trajceska L, van Oeveren W, Smit AJ, Dzekova P, Stegmayr B, Sikole A, Rakhorst G, Graaff R. Eur J Clin Nutr. 2015 Mar;69(3):410.

  27. Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function. Boertien WE, Meijer E, de Jong PE, ter Horst GJ, Renken RJ, van der Jagt EJ, Kappert P, Ouyang J, Engels GE, van Oeveren W, Struck J, Czerwiec FS, Oberdhan D, Krasa HB, Gansevoort RT. Am J Kidney Dis. 2015 Jun;65(6):833-41.

  28. The influence of body mass index on the accumulation of advanced glycation end products in hemodialysis patients. Arsov S, Trajceska L, van Oeveren W, Smit AJ, Dzekova P, Stegmayr B, Sikole A, Rakhorst G, Graaff R. Eur J Clin Nutr. 2015 Mar;69(3):309-13.

  29. Cerebral near infrared spectroscopy oximetry in extremely preterm infants: phase II randomised clinical trial. Hyttel-Sorensen S, Pellicer A, Alderliesten T, Austin T, van Bel F, Benders M, Claris O, Dempsey E, Franz AR, Fumagalli M, Gluud C, Grevstad B, Hagmann C, Lemmers P, van Oeveren W, Pichler G, Plomgaard AM, Riera J, Sanchez L, Winkel P, Wolf M, Greisen G. BMJ. 2015 Jan 5;350:g7635.

  30. Effects of cell-saving devices and filters on transfusion in cardiac surgery: a multicenter randomized study. Vermeijden WJ, van Klarenbosch J, Gu YJ, Mariani MA, Buhre WF, Scheeren TW, Hagenaars JA, Tan ME, Haenen JS, Bras L, van Oeveren W, van den Heuvel ER, de Vries AJ. Ann Thorac Surg. 2015 Jan;99(1):26-32.

  31. The effect of pulsatile cardiopulmonary bypass on lung function in elderly patients. Engels GE, Dodonov M, Rakhorst G, van Oeveren W, Milano AD, Gu YJ, Faggian G. Int J Artif Organs. 2014 Sep;37(9):679-87.

  32. In vitro air removal characteristics of two neonatal cardiopulmonary bypass systems: filtration may lead to fractionation of bubbles. Stehouwer MC, Kelder JC, van Oeveren W, de Vroege R. Int J Artif Organs. 2014 Sep;37(9):688-96.

  33. Pulsatile cardiopulmonary bypass and renal function in elderly patients undergoing aortic valve surgery†. Milano AD, Dodonov M, van Oeveren W, Onorati F, Gu YJ, Tessari M, Menon T, Gottin L, Faggian G. Eur J Cardiothorac Surg. 2015 Feb;47(2):291-8; discussion 298.

  34. Hemodialysis-induced regional left ventricular systolic dysfunction and inflammation: a cross-sectional study. Assa S, Hummel YM, Voors AA, Kuipers J, Westerhuis R, Groen H, Bakker SJ, Muller Kobold AC, van Oeveren W, Struck J, de Jong PE, Franssen CF. Am J Kidney Dis. 2014 Aug;64(2):265-73.

  35. Obstacles in haemocompatibility testing. van Oeveren W. Scientifica (Cairo). 2013;2013:392584.

  36. Skin and plasma autofluorescence during hemodialysis: a pilot study. Graaff R, Arsov S, Ramsauer B, Koetsier M, Sundvall N, Engels GE, Sikole A, Lundberg L, Rakhorst G, Stegmayr B. Artif Organs. 2014 Jun;38(6):515-8.

  37. Neurological injury after neonatal cardiac surgery: a randomized, controlled trial of 2 perfusion techniques. Algra SO, Jansen NJ, van der Tweel I, Schouten AN, Groenendaal F, Toet M, van Oeveren W, van Haastert IC, Schoof PH, de Vries LS, Haas F. Circulation. 2014 Jan 14;129(2):224-33.

  38. [Modified polyurethane foam as a local hemostatic agent after dental extractions]. Selten MH, Broekema FI, Zuidema J, van Oeveren W, Bos RR. Ned Tijdschr Tandheelkd. 2013 Jul-Aug;120(7-8):378-82. Dutch.

  39. The SafeBoosC phase II randomised clinical trial: a treatment guideline for targeted near-infrared-derived cerebral tissue oxygenation versus standard treatment in extremely preterm infants. Pellicer A, Greisen G, Benders M, Claris O, Dempsey E, Fumagalli M, Gluud C, Hagmann C, Hellström-Westas L, Hyttel-Sorensen S, Lemmers P, Naulaers G, Pichler G, Roll C, van Bel F, van Oeveren W, Skoog M, Wolf M, Austin T. Neonatology. 2013;104(3):171-8.

  40. A phase II randomized clinical trial on cerebral near-infrared spectroscopy plus a treatment guideline versus treatment as usual for extremely preterm infants during the first three days of life (SafeBoosC): study protocol for a randomized controlled trial. Hyttel-Sorensen S, Austin T, van Bel F, Benders M, Claris O, Dempsey E, Fumagalli M, Greisen G, Grevstad B, Hagmann C, Hellström-Westas L, Lemmers P, Lindschou J, Naulaers G, van Oeveren W, Pellicer A, Pichler G, Roll C, Skoog M, Winkel P, Wolf M, Gluud C. Trials. 2013 May 1;14:120.

  41. Flush at room temperature followed by storage on ice creates the best lung graft preservation in rats. Munneke AJ, Rakhorst G, Petersen AH, van Oeveren W, Prop J, Erasmus ME. Transpl Int. 2013 Jul;26(7):751-60.

  42. Increase in skin autofluorescence and release of heart-type fatty acid binding protein in plasma predicts mortality of hemodialysis patients. Arsov S, Trajceska L, van Oeveren W, Smit AJ, Dzekova P, Stegmayr B, Sikole A, Rakhorst G, Graaff R. Artif Organs. 2013 Jul;37(7):E114-22.

  43. Advanced glycation end-products and skin autofluorescence in end-stage renal disease: a review. Arsov S, Graaff R, van Oeveren W, Stegmayr B, Sikole A, Rakhorst G, Smit AJ. Clin Chem Lab Med. 2014 Jan 1;52(1):11-20.

  44. Glomerular and tubular damage markers in individuals with progressive albuminuria. Nauta FL, Scheven L, Meijer E, van Oeveren W, de Jong PE, Bakker SJ, Gansevoort RT. Clin J Am Soc Nephrol. 2013 Jul;8(7):1106-14.

  45. In situ lung perfusion is a valuable tool to assess lungs from donation after circulatory death donors category I-II. Van De Wauwer C, Munneke AJ, Engels GE, Berga FM, Rakhorst G, Nijsten MW, Mariani MA, Erasmus ME. Transpl Int. 2013 May;26(5):485-92.

  46. Clinical use of cerebral oximetry in extremely preterm infants is feasible. Hyttel-Sørensen S, Austin T, van Bel F, Benders M, Claris O, Dempsey EM, Fumagalli M, Gluud C, Hagmann C, Hellström-Westas L, Lemmers P, Naulaers G, van Oeveren W, Pellicer A, Pichler G, Roll C, Støy LS, Wolf M, Greisen G. Dan Med J. 2013 Jan;60(1):A4533.

  47. The utility of lung epithelium specific biomarkers in cardiac surgery: a comparison of biomarker profiles in on- and off-pump coronary bypass surgery. Engels GE, Gu YJ, van Oeveren W, Rakhorst G, Mariani MA, Erasmus ME. J Cardiothorac Surg. 2013 Jan 9;8:4.

  48. Effect of minimized perfusion circuit on brain injury markers carnosinase and brain-type fatty binding protein in coronary artery bypass grafting patients. Pahari DR, Gu YJ, van Oeveren W, El-Essawi A, Harringer W, Brouwer RM. Artif Organs. 2013 Feb;37(2):128-35.

  49. In vivo hemostatic efficacy of polyurethane foam compared to collagen and gelatin. Broekema FI, van Oeveren W, Selten MH, Meijer RJ, de Wolf JT, Bos RR. Clin Oral Investig. 2013 May;17(4):1273-8.

  50. Comparison of modified chandler, roller pump, and ball valve circulation models for in vitro testing in high blood flow conditions: application in thrombogenicity testing of different materials for vascular applications. van Oeveren W, Tielliu IF, de Hart J. Int J Biomater. 2012;2012:673163.

  51. Low-flow antegrade cerebral perfusion attenuates early renal and intestinal injury during neonatal aortic arch reconstruction. Algra SO, Schouten AN, van Oeveren W, van der Tweel I, Schoof PH, Jansen NJ, Haas F. J Thorac Cardiovasc Surg. 2012 Dec;144(6):1323-8, 1328.e1-2.

  52. In vitro haemocompatibility of a novel bioprosthetic total artificial heart. Jansen P, van Oeveren W, Capel A, Carpentier A. Eur J Cardiothorac Surg. 2012 Jun;41(6):e166-72.

  53. Effect of frozen storage on urinary concentration of kidney damage markers. Nauta FL, Bakker SJ, Lambers Heerspink H, de Zeeuw D, van Oeveren W, Bilo H, de Jong PE, Gansevoort RT. Am J Kidney Dis. 2012 Apr;59(4):586-9.

  54. Polyacylurethanes as Novel Degradable Cell Carrier Materials for Tissue Engineering. Jovanovic D, Roukes FV, Löber A, Engels GE, Oeveren WV, Seijen XJGV, Luyn MJAV, Harmsen MC, Schouten AJ. Materials (Basel). 2011 Oct 6;4(10):1705-1727.

  55. Volume status and diuretic therapy in systolic heart failure and the detection of early abnormalities in renal and tubular function. Damman K, Ng Kam Chuen MJ, MacFadyen RJ, Lip GY, Gaze D, Collinson PO, Hillege HL, van Oeveren W, Voors AA, van Veldhuisen DJ. J Am Coll Cardiol. 2011 May 31;57(22):2233-41.

  56. Albuminuria, proteinuria, and novel urine biomarkers as predictors of long-term allograft outcomes in kidney transplant recipients. Nauta FL, Bakker SJ, van Oeveren W, Navis G, van der Heide JJ, van Goor H, de Jong PE, Gansevoort RT. Am J Kidney Dis. 2011 May;57(5):733-43.

  57. In vitro analysis of polyurethane foam as a topical hemostatic agent. Broekema FI, van Oeveren W, Zuidema J, Visscher SH, Bos RR. J Mater Sci Mater Med. 2011 Apr;22(4):1081-6.

  58. Clinical effectiveness of centrifugal pump to produce pulsatile flow during cardiopulmonary bypass in patients undergoing cardiac surgery. Gu YJ, van Oeveren W, Mungroop HE, Epema AH, den Hamer IJ, Keizer JJ, Leuvenink RP, Mariani MA, Rakhorst G. Artif Organs. 2011 Feb;35(2):E18-26.

  59. Glomerular and tubular damage markers are elevated in patients with diabetes. Nauta FL, Boertien WE, Bakker SJ, van Goor H, van Oeveren W, de Jong PE, Bilo H, Gansevoort RT. Diabetes Care. 2011 Apr;34(4):975-81.

  60. Invited commentary. Gu JY, Engels GE, van Oeveren W. Ann Thorac Surg. 2011 Feb;91(2):540-1.

  61. Association of urinary biomarkers with disease severity in patients with autosomal dominant polycystic kidney disease: a cross-sectional analysis. Meijer E, Boertien WE, Nauta FL, Bakker SJ, van Oeveren W, Rook M, van der Jagt EJ, van Goor H, Peters DJ, Navis G, de Jong PE, Gansevoort RT. Am J Kidney Dis. 2010 Nov;56(5):883-95.

  62. The value of machine perfusion perfusate biomarkers for predicting kidney transplant outcome. Moers C, Varnav OC, van Heurn E, Jochmans I, Kirste GR, Rahmel A, Leuvenink HG, Squifflet JP, Paul A, Pirenne J, van Oeveren W, Rakhorst G, Ploeg RJ. Transplantation. 2010 Nov 15;90(9):966-73.

  63. Endotoxin release in cardiac surgery with cardiopulmonary bypass: pathophysiology and possible therapeutic strategies. An update. Kats S, Schönberger JP, Brands R, Seinen W, van Oeveren W. Eur J Cardiothorac Surg. 2011 Apr;39(4):451-8.

  64. Impact of platelet adhesion on thromboelastometry in dilutional consumption coagulopathy with either HES or gelatin. Huet R, de Vries AJ, Cernak V, van Oeveren W. Acta Anaesthesiol Scand. 2010 Jul;54(6):783-4.

  65. Novel polyurethanes with interconnected porous structure induce in vivo tissue remodeling and accompanied vascularization. Jovanovic D, Engels GE, Plantinga JA, Bruinsma M, van Oeveren W, Schouten AJ, van Luyn MJ, Harmsen MC. J Biomed Mater Res A. 2010 Oct;95(1):198-208.

  66. The effects of cryopreservation on red blood cell rheologic properties. Henkelman S, Lagerberg JW, Graaff R, Rakhorst G, van Oeveren W. Transfusion. 2010 Nov;50(11):2393-401.

  67. A double-blind, randomized, placebo-controlled clinical trial on benfotiamine treatment in patients with diabetic nephropathy. Alkhalaf A, Klooster A, van Oeveren W, Achenbach U, Kleefstra N, Slingerland RJ, Mijnhout GS, Bilo HJ, Gans RO, Navis GJ, Bakker SJ. Diabetes Care. 2010 Jul;33(7):1598-601.

  68. The effect of vacuum mixing and pre-heating the femoral component on the mechanical properties of the cement mantle. Baleani M, Bialoblocka-Juszczyk E, Engels GE, Viceconti M. J Bone Joint Surg Br. 2010 Mar;92(3):454-60.

  69. Microfiltration sampling in rats and in cows: toward a portable device for continuous glucocorticoid hormone sampling. Huinink KD, Lambooij B, Jansen-van Zelm K, Cremers TI, van Oeveren W, Bakker PL, Venema K, Westerink BH, Korf J. Analyst. 2010 Feb;135(2):390-6.

  70. Is red blood cell rheology preserved during routine blood bank storage? Henkelman S, Dijkstra-Tiekstra MJ, de Wildt-Eggen J, Graaff R, Rakhorst G, van Oeveren W. Transfusion. 2010 Apr;50(4):941-8.

  71. Does hepatitis C increase the accumulation of advanced glycation end products in haemodialysis patients? Arsov S, Graaff R, Morariu AM, van Oeveren W, Smit AJ, Busletic I, Trajcevska L, Selim G, Dzekova P, Stegmayr B, Sikole A, Rakhorst G. Nephrol Dial Transplant. 2010 Mar;25(3):885-91.

  72. Spatiotemporal progression of localized bacterial peritonitis before and after open abdomen lavage monitored by in vivo bioluminescent imaging. Sharma PK, Engels E, van Oeveren W, Ploeg RJ, van Henny der Mei C, Busscher HJ, Van Dam GM, Rakhorst G. Surgery. 2010 Jan;147(1):89-97.

  73. The association of hemodilution and transfusion of red blood cells with biochemical markers of splanchnic and renal injury during cardiopulmonary bypass. Huybregts RA, de Vroege R, Jansen EK, van Schijndel AW, Christiaans HM, van Oeveren W. Anesth Analg. 2009 Aug;109(2):331-9.

  74. Leucocyte filtration of salvaged blood during cardiac surgery: effect on red blood cell function in concentrated blood compared with diluted blood. Gu YJ, de Vries AJ, Hagenaars JA, van Oeveren W. Eur J Cardiothorac Surg. 2009 Nov;36(5):877-82.

  75. Effects of acidosis, alkalosis, hyperthermia and hypothermia on haemostasis: results of point-of-care testing with the thromboelastography analyser. Ramaker AJ, Meyer P, van der Meer J, Struys MM, Lisman T, van Oeveren W, Hendriks HG. Blood Coagul Fibrinolysis. 2009 Sep;20(6):436-9.

  76. Iron-induced platelet aggregation measurement: a novel method to measure platelet function in stenting for ST segment elevation myocardial infarction. Smit JJ, van Oeveren W, Ottervanger JP, Slingerland RJ, Remijn JA, Zijlstra F, van ‘t Hof AW. Eur J Clin Invest. 2009 Feb;39(2):103-9.

  77. Influence of mechanical cell salvage on red blood cell aggregation, deformability, and 2,3-diphosphoglycerate in patients undergoing cardiac surgery with cardiopulmonary bypass. Gu YJ, Vermeijden WJ, de Vries AJ, Hagenaars JA, Graaff R, van Oeveren W. Ann Thorac Surg. 2008 Nov;86(5):1570-5.

  78. Do repeated runs of a cell saver device increase the pro-inflammatory properties of washed blood? Vermeijden WJ, Hagenaars A, van Oeveren W, de Vries AJ. Eur J Cardiothorac Surg. 2008 Aug;34(2):350-3.

  79. Changes in glomerular filtration rate after cardiac surgery with cardiopulmonary bypass in patients with mild preoperative renal dysfunction. Loef BG, Henning RH, Navis G, Rankin AJ, van Oeveren W, Ebels T, Epema AH. Br J Anaesth. 2008 Jun;100(6):759-64.

  80. A new system for right atrial cooling. Huybregts MA, de Vroege R, van Oeveren W. Ann Thorac Surg. 2008 Apr;85(4):1421-4.

  81. Early events in kidney donation: progression of endothelial activation, oxidative stress and tubular injury after brain death. Morariu AM, Schuurs TA, Leuvenink HG, van Oeveren W, Rakhorst G, Ploeg RJ. Am J Transplant. 2008 May;8(5):933-41.

  82. The clinical effects and mechanisms of leukocyte depletion filters during cardiac surgery. de Vries AJ, Gu DY, van Oeveren W. Ann Card Anaesth. 2005 Jul;8(2):117-24. No abstract available.

  83. Cell Saver device efficiently removes cell-derived microparticles during cardiac surgery. van den Goor JM, Nieuwland R, van Oeveren W, Rutten PM, Tijssen JG, Hau CM, Sturk A, Eijsman L, de Mol BA. J Thorac Cardiovasc Surg. 2007 Sep;134(3):798-9. No abstract available.

  84. Attenuated renal and intestinal injury after use of a mini-cardiopulmonary bypass system. Huybregts RA, Morariu AM, Rakhorst G, Spiegelenberg SR, Romijn HW, de Vroege R, van Oeveren W. Ann Thorac Surg. 2007 May;83(5):1760-6.

  85. Washing of stored red blood cells by an autotransfusion device before transfusion. de Vroege R, Wildevuur WR, Muradin JA, Graves D, van Oeveren W. Vox Sang. 2007 Feb;92(2):130-5.

  86. Children undergoing cardiac surgery for complex cardiac defects show imbalance between pro- and anti-thrombotic activity. Heying R, van Oeveren W, Wilhelm S, Schumacher K, Grabitz RG, Messmer BJ, Seghaye MC. Crit Care. 2006;10(6):R165.

  87. Adhesion of thrombotic components to the surface of a clinically used oxygenator is not affected by Trillium coating. van den Goor JM, van Oeveren W, Rutten PM, Tijssen JG, Eijsman L. Perfusion. 2006 May;21(3):165-72.

  88. Acute isovolemic hemodilution triggers proinflammatory and procoagulatory endothelial activation in vital organs: role of erythrocyte aggregation. Morariu AM, Maathuis MH, Asgeirsdottir SA, Leuvenink HG, Boonstra PW, van Oeveren W, Ploeg RJ, Molema I, Rakhorst G. Microcirculation. 2006 Jul-Aug;13(5):397-409.

  89. Clinical efficacy and biocompatibility of three different leukocyte and fat removal filters during cardiac surgery. de Vries AJ, Vermeijden WJ, Gu YJ, Hagenaars JA, van Oeveren W. Artif Organs. 2006 Jun;30(6):452-7.

  90. Dexamethasone: benefit and prejudice for patients undergoing on-pump coronary artery bypass grafting: a study on myocardial, pulmonary, renal, intestinal, and hepatic injury. Morariu AM, Loef BG, Aarts LP, Rietman GW, Rakhorst G, van Oeveren W, Epema AH. Chest. 2005 Oct;128(4):2677-87.

  91. PMEA polymer-coated PVC tubing maintains anti-thrombogenic properties during in vitro whole blood circulation. Yoshizaki T, Tabuchi N, van Oeveren W, Shibamiya A, Koyama T, Sunamori M. Int J Artif Organs. 2005 Aug;28(8):834-40.

  92. Influence of hemodilution of plasma proteins on erythrocyte aggregability: an in vivo study in patients undergoing cardiopulmonary bypass. Gu YJ, Graaff R, de Hoog E, Veeger NJ, Panday G, Boonstra PW, van Oeveren W. Clin Hemorheol Microcirc. 2005;33(2):95-107.

  93. The impact of heparin-coated circuits on hemodynamics during and after cardiopulmonary bypass. de Vroege R, Huybregts R, van Oeveren W, van Klarenbosch J, Linley G, Mutlu J, Jansen E, Hack E, Eijsman L, Wildevuur C. Artif Organs. 2005 Jun;29(6):490-7.

  94. Effect of brain death and non-heart-beating kidney donation on renal function and injury: an assessment in the isolated perfused rat kidney. van den Eijnden MM, Leuvenink HG, Ottens PJ, ‘t Hart NA, van Oeveren W, Morariu AM, van Goor H, Ploeg RJ. Exp Clin Transplant. 2003 Dec;1(2):85-95.

  95. The impact of heparin coated circuits upon metabolism in vital organs: effect upon cerebral and renal function during and after cardiopulmonary bypass. de Vroege R, Stooker W, van Oeveren W, Bakker EW, Huybregts RA, van Klarenbosch J, van Kamp GJ, Hack CE, Eijsman L, Wildevuur CR. ASAIO J. 2005 Jan-Feb;51(1):103-9.

  96. Augmentation of abdominal organ perfusion during cardiopulmonary bypass with a novel intra-aortic pulsatile catheter pump. Gu YJ, De Kroon TL, Elstrodt JM, van Oeveren W, Boonstra PW, Rakhorst G. Int J Artif Organs. 2005 Jan;28(1):35-43.

  97. Leucocyte filtration of residual heart-lung machine blood in children undergoing congenital heart surgery. de Vries AJ, Gu YJ, van Oeveren W. Perfusion. 2004 Nov;19(6):345-9.

  98. Reduced complement activation during cardiopulmonary bypass does not affect the postoperative acute phase response. van den Goor J, Nieuwland R, van den Brink A, van Oeveren W, Rutten P, Tijssen J, Eijsman L. Eur J Cardiothorac Surg. 2004 Nov;26(5):926-31.

  99. Invited commentary. van Oeveren W. Ann Thorac Surg. 2004 Nov;78(5):1577-8. No abstract available.

  100. Clopidogrel and postoperative bleeding. Boonstra PW, van Oeveren W. Ann Thorac Surg. 2004 Nov;78(5):1522. No abstract available.

  101. Induction and detection of disturbed homeostasis in cardiopulmonary bypass. de Vroege R, te Meerman F, Eijsman L, Wildevuur WR, Wildevuur ChR, van Oeveren W. Perfusion. 2004;19(5):267-76. Review.

  102. Effect of dexamethasone on perioperative renal function impairment during cardiac surgery with cardiopulmonary bypass. Loef BG, Henning RH, Epema AH, Rietman GW, van Oeveren W, Navis GJ, Ebels T. Br J Anaesth. 2004 Dec;93(6):793-8. Epub 2004 Sep 17.

  103. Analysis of red blood cell aggregation in cardio-pulmonary bypass (CPB) surgery. Graaff R, Gu YJ, Boonstra PW, van Oeveren W, Rakhorst G. Int J Artif Organs. 2004 Jun;27(6):488-94.

  104. Impaired platelet inhibitory effect of a single dose of acetylsalicylic acid in patients with unstable coronary artery syndrome in comparison with healthy volunteers. Smit JJ, Hoorntje JC, Miedema K, van Oeveren W. Neth Heart J. 2004 Jun;12(6):265-270.

  105. The impact of heparin-coated cardiopulmonary bypass circuits on pulmonary function and the release of inflammatory mediators. de Vroege R, van Oeveren W, van Klarenbosch J, Stooker W, Huybregts MA, Hack CE, van Barneveld L, Eijsman L, Wildevuur CR. Anesth Analg. 2004 Jun;98(6):1586-94, table of contents.

  106. Clinical evaluation of a new fat removal filter during cardiac surgery. de Vries AJ, Gu YJ, Douglas YL, Post WJ, Lip H, van Oeveren W. Eur J Cardiothorac Surg. 2004 Feb;25(2):261-6.

  107. Activation of the inflammatory reaction within minutes after birth in ventilated preterm lambs with neonatal respiratory distress syndrome. Jaarsma AS, Braaksma MA, Geven WB, van Oeveren W, Bambang Oetomo S. Biol Neonate. 2004;86(1):1-5. Epub 2004 Jan 21.

  108. In vitro degradation and biocompatibility of poly(DL-lactide-epsilon-caprolactone) nerve guides. Meek MF, Jansen K, Steendam R, van Oeveren W, van Wachem PB, van Luyn MJ. J Biomed Mater Res A. 2004 Jan 1;68(1):43-51.

  109. Antenatal glucocorticoids attenuate activation of the inflammatory reaction and clotting in preterm lambs. Jaarsma AS, Braaksma MA, Geven WB, van Oeveren W, Bambang-Oetomo S. Biol Neonate. 2004;85(2):82-9. Epub 2003 Nov 19.

  110. Serum carnosinase activity in plasma and serum: validation of a method and values in cardiopulmonary bypass surgery. Schoen P, Everts H, de Boer T, van Oeveren W. Clin Chem. 2003 Nov;49(11):1930-2. No abstract available.

  111. Generation of platelet-derived microparticles in patients undergoing cardiac surgery is not affected by complement activation. van den Goor JM, van den Brink A, Nieuwland R, van Oeveren W, Rutten PM, Tepaske R, Tijssen JG, Sturk A, de Mol BA, Eijsman L. J Thorac Cardiovasc Surg. 2003 Oct;126(4):1101-6.

  112. On the influence of flow conditions and wettability on blood material interactions. Spijker HT, Graaff R, Boonstra PW, Busscher HJ, van Oeveren W. Biomaterials. 2003 Nov;24(26):4717-27. Review.

  113. Time course of proinflammatory and anti-inflammatory responses after cardiac operation: monocyte HLA-DR expression. Gu YJ, van Oeveren W. Ann Thorac Surg. 2003 Aug;76(2):654-5; author reply 655-6. No abstract available.

  114. Leucocyte depletion during cardiac surgery: a comparison of different filtration strategies. de Vries AJ, Gu YJ, Post WJ, Vos P, Stokroos I, Lip H, van Oeveren W. Perfusion. 2003 Mar;18(1):31-8.

  115. Influence of abciximab on the adhesion of platelets on a shielded plasma gradient prepared on polyethylene. Spijker HT, Busscher HJ, van Oeveren W. Thromb Res. 2002 Oct 1;108(1):57-62.

  116. Increased neutrophil priming and sensitization before commencing cardiopulmonary bypass in cardiac surgical patients. Gu YJ, Schoen P, Tigchelaar I, Loef BG, Ebels T, Rankin AJ, van Oeveren W. Ann Thorac Surg. 2002 Oct;74(4):1173-9.

  117. Comparison of coagulation activity tests in vitro for selected biomaterials. van Oeveren W, Haan J, Lagerman P, Schoen P. Artif Organs. 2002 Jun;26(6):506-11.

  118. The rationale for fat filtration during cardiac surgery. de Vries AJ, Gu YJ, van Oeveren W. Perfusion. 2002 May;17 Suppl:29-33. Review.

  119. Effect of biologically active coating on biocompatibility of Nitinol devices designed for the closure of intra-atrial communications. Kong X, Grabitz RG, van Oeveren W, Klee D, van Kooten TG, Freudenthal F, Qing M, von Bernuth G, Seghaye MC. Biomaterials. 2002 Apr;23(8):1775-83.

  120. Off-pump coronary revascularization attenuates transient renal damage compared with on-pump coronary revascularization. Loef BG, Epema AH, Navis G, Ebels T, van Oeveren W, Henning RH. Chest. 2002 Apr;121(4):1190-4.

  121. Platelet adhesion and activation on a shielded plasma gradient prepared on polyethylene. Spijker HT, Bos R, Busscher HJ, van Kooten T, van Oeveren W. Biomaterials. 2002 Feb;23(3):757-66.

  122. Superhydrophobic modification fails to improve the performance of small diameter expanded polytetrafluoroethylene vascular grafts. Toes GJ, van Muiswinkel KW, van Oeveren W, Suurmeijer AJ, Timens W, Stokroos I, van den Dungen JJ. Biomaterials. 2002 Jan;23(1):255-62.

  123. Early activation of inflammation and clotting in the preterm lamb with neonatal RDS: comparison of conventional ventilation and high frequency oscillatory ventilation. Jaarsma AS, Braaksma MA, Geven WB, van Oeveren W, Oetomo SB. Pediatr Res. 2001 Nov;50(5):650-7.

  124. Eptifibatide and abciximab exhibit equivalent antiplatelet efficacy in an experimental model of stenting in both healthy volunteers and patients with coronary artery disease. Amoroso G, van Boven AJ, van Veldhuisen DJ, Tio RA, Baljé-Volkers CP, Petronio AS, van Oeveren W. J Cardiovasc Pharmacol. 2001 Oct;38(4):633-41.

  125. Is the use of albumin in colloid prime solution of cardiopulmonary bypass circuit justified? Boks RH, van Herwerden LA, Takkenberg JJ, van Oeveren W, Gu YJ, Wijers MJ, Bogers AJ. Ann Thorac Surg. 2001 Sep;72(3):850-3.

  126. Multilink stent promotes less platelet and leukocyte adhesion than a traditional stainless steel stent: an in vitro experimental study. Amoroso G, van Boven AJ, Volkers C, Crijns HJ, van Oeveren W. J Investig Med. 2001 May;49(3):265-72.

  127. Is there a relationship between cognitive dysfunction and systemic inflammatory response after cardiopulmonary bypass? Westaby S, Saatvedt K, White S, Katsumata T, van Oeveren W, Halligan PW. Ann Thorac Surg. 2001 Feb;71(2):667-72.

  128. Comparison of three commercially available hollow fiber oxygenators: gas transfer performance and biocompatibility. de Vroege R, Wagemakers M, te Velthuis H, Bulder E, Paulus R, Huybregts R, Wildevuur W, Eijsman L, van Oeveren W, Wildevuur C. ASAIO J. 2001 Jan-Feb;47(1):37-44.

  129. A novel hydroxyethyl starch (Voluven) for effective perioperative plasma volume substitution in cardiac surgery. Gallandat Huet RC, Siemons AW, Baus D, van Rooyen-Butijn WT, Haagenaars JA, van Oeveren W, Bepperling F. Can J Anaesth. 2000 Dec;47(12):1207-15.

  130. Phosphorylcholine coating of extracorporeal circuits provides natural protection against blood activation by the material surface. De Somer F, François K, van Oeveren W, Poelaert J, De Wolf D, Ebels T, Van Nooten G. Eur J Cardiothorac Surg. 2000 Nov;18(5):602-6.

  131. Filtration of activated granulocytes during cardiopulmonary bypass surgery: a morphologic and immunologic study to characterize the trapped leukocytes. Smit JJ, de Vries AJ, Gu YJ, van Oeveren W. J Lab Clin Med. 2000 Mar;135(3):238-46.

  132. Pressure drop, shear stress, and activation of leukocytes during cardiopulmonary bypass: a comparison between hollow fiber and flat sheet membrane oxygenators. Gu YJ, Boonstra PW, Graaff R, Rijnsburger AA, Mungroop H, van Oeveren W. Artif Organs. 2000 Jan;24(1):43-8.

  133. Efficiency and safety of leukocyte filtration during cardiopulmonary bypass for cardiac surgery. Smit JJ, de Vries AJ, Gu YJ, van Oeveren W. Transfus Sci. 1999 Jun;20(3):151-65.

  134. Is there a relationship between serum S-100beta protein and neuropsychologic dysfunction after cardiopulmonary bypass? Westaby S, Saatvedt K, White S, Katsumata T, van Oeveren W, Bhatnagar NK, Brown S, Halligan PW. J Thorac Cardiovasc Surg. 2000 Jan;119(1):132-7.

  135. Complement activation in coronary artery bypass grafting patients without cardiopulmonary bypass: the role of tissue injury by surgical incision. Gu YJ, Mariani MA, Boonstra PW, Grandjean JG, van Oeveren W. Chest. 1999 Oct;116(4):892-8.

  136. Fluorescence labeling to study platelet and leucocyte deposition onto vascular grafts in vitro. Toes GJ, van den Dungen JJ, Haan J, Hermens RA, van Oeveren W. Biomaterials. 1999 Oct;20(20):1951-8.

  137. Silicon-carbide coated coronary stents have low platelet and leukocyte adhesion during platelet activation. Monnink SH, van Boven AJ, Peels HO, Tigchelaar I, de Kam PJ, Crijns HJ, van Oeveren W. J Investig Med. 1999 Jul;47(6):304-10.

  138. Procoagulant activity after off-pump coronary operation: is the current anticoagulation adequate? Mariani MA, Gu YJ, Boonstra PW, Grandjean JG, van Oeveren W, Ebels T. Ann Thorac Surg. 1999 May;67(5):1370-5.

  139. Effect of normoxic cardiopulmonary bypass on leukocyte elastase release. Gu YJ, Boonstra PW, van Oeveren W. J Thorac Cardiovasc Surg. 1999 May;117(5):1045-6. No abstract available.

  140. Leukocyte depletion during cardiac operation: a new approach through the venous bypass circuit. Gu YJ, de Vries AJ, Vos P, Boonstra PW, van Oeveren W. Ann Thorac Surg. 1999 Mar;67(3):604-9.

  141. Increased tissue-type plasminogen activator antigen release is not accompanied by increased systemic fibrinolytic activity in severe neonatal respiratory distress syndrome. Brus F, Oetomo SB, Schieving J, Groothuis E, Okken A, van Oeveren W. Pediatr Res. 1999 Apr;45(4 Pt 1):588-94.

  142. Blood damage, platelet and clotting activation during application of radiofrequency or cryoablation catheters: a comparative in vitro study. van Oeveren W, Crijns HJ, Korteling BJ, Wegereef EW, Haan J, Tigchelaar I, Hoekstra A. J Med Eng Technol. 1999 Jan-Feb;23(1):20-5.

  143. Time-related contact angle measurements with human plasma on biomaterial surfaces. Rakhorst G, Van der Mei HC, van Oeveren W, Spijker HT, Busscher HJ. Int J Artif Organs. 1999 Jan;22(1):35-9.

  144. Platelets and soluble fibrin promote plasminogen activation causing downregulation of platelet glycoprotein Ib/IX complexes: protection by aprotinin. de Haan J, van Oeveren W. Thromb Res. 1998 Nov 15;92(4):171-9.

  145. Comparison of three plasma expanders used as priming fluids in cardiopulmonary bypass patients. Tigchelaar I, Gallandat Huet RC, Boonstra PW, van Oeveren W. Perfusion. 1998 Sep;13(5):297-303.

  146. Heparin-coated bypass circuits: effects on inflammatory response in pediatric cardiac operations. Schreurs HH, Wijers MJ, Gu YJ, van Oeveren W, van Domburg RT, de Boer JH, Bogers AJ. Ann Thorac Surg. 1998 Jul;66(1):166-71.

  147. The use of the gastroepiploic artery for peripheral revascularisation. A study in pigs. Toes GJ, van Geel PP, van den Dungen JJ, Buikema H, Grandjean JG, Verhoeven EL, van Oeveren W, Timens W. Eur J Vasc Endovasc Surg. 1998 Apr;15(4):320-6.

  148. Cardiopulmonary bypass circuit treated with surface-modifying additives: a clinical evaluation of blood compatibility. Gu YJ, Boonstra PW, Rijnsburger AA, Haan J, van Oeveren W. Ann Thorac Surg. 1998 May;65(5):1342-7.

  149. Reduction of the inflammatory response in patients undergoing minimally invasive coronary artery bypass grafting. Gu YJ, Mariani MA, van Oeveren W, Grandjean JG, Boonstra PW. Ann Thorac Surg. 1998 Feb;65(2):420-4.

  150. Number and activation of circulating polymorphonuclear leukocytes and platelets are associated with neonatal respiratory distress syndrome severity. Brus F, van Oeveren W, Okken A, Oetomo SB. Pediatrics. 1997 May;99(5):672-80.

  151. Hemostatic effects of three colloid plasma substitutes for priming solution in cardiopulmonary bypass. Tigchelaar I, Gallandat Huet RC, Korsten J, Boonstra PW, van Oeveren W. Eur J Cardiothorac Surg. 1997 Apr;11(4):626-32.

  152. Blood interaction with a Bioline heparin coated HIA-VAD: a study on calves. van der Kamp KW, Magielse CP, Elstrodt JM, van der Meer J, van Oeveren W, Rakhorst G. Int J Artif Organs. 1997 Jan;20(1):43-50.

  153. Disease severity is correlated with plasma clotting and fibrinolytic and kinin-kallikrein activity in neonatal respiratory distress syndrome. Brus F, van Oeveren W, Okken A, Oetomo SB. Pediatr Res. 1997 Jan;41(1):120-7.

  154. Clotting and fibrinolytic disturbance during lung transplantation: effect of low-dose aprotinin. Groningen Lung Transplant Group. Gu YJ, de Haan J, Brenken UP, de Boer WJ, Prop J, van Oeveren W. J Thorac Cardiovasc Surg. 1996 Sep;112(3):599-606.

  155. Leukocyte depletion results in improved lung function and reduced inflammatory response after cardiac surgery. Gu YJ, de Vries AJ, Boonstra PW, van Oeveren W. J Thorac Cardiovasc Surg. 1996 Aug;112(2):494-500.

  156. In vitro effect of hemodilution on activated clotting time and high-dose thrombin time during cardiopulmonary bypass. Huyzen RJ, van Oeveren W, Wei F, Stellingwerf P, Boonstra PW, Gu YJ. Ann Thorac Surg. 1996 Aug;62(2):533-7.

  157. Extrinsic pathway–associated activated clotting time for anticoagulation monitoring during cardiopulmonary bypass. Gu YJ, Huyzen RJ, van Oeveren W. Anesth Analg. 1996 Aug;83(2):433. No abstract available.

  158. Leakage of protein into lungs of preterm ventilated rabbits is correlated with activation of clotting, complement, and polymorphonuclear leukocytes in plasma. Brus F, van Oeveren W, Heikamp A, Okken A, Oetomo SB. Pediatr Res. 1996 Jun;39(6):958-65.

  159. Inhibition of vein graft intimal and medial thickening by periadventitial application of a sulfated carbohydrate polymer. Toes GJ, Barnathan ES, Liu H, Raghunath PN, Tomaszewski JE, Caron RJ, Weisz PB, van Oeveren W, Golden MA. J Vasc Surg. 1996 Apr;23(4):650-6.

  160. Activation of circulating polymorphonuclear leukocytes in preterm infants with severe idiopathic respiratory distress syndrome. Brus F, van Oeveren W, Okken A, Bambang SO. Pediatr Res. 1996 Mar;39(3):456-63.

  161. Intrinsic pathway-dependent activated clotting time is not reliable for monitoring anticoagulation during cardiopulmonary bypass in neonates. Gu YJ, Huyzen RJ, van Oeveren W. J Thorac Cardiovasc Surg. 1996 Mar;111(3):677-8. No abstract available.

  162. Effect of intraperitoneal antimicrobials on the concentration of bacteria, endotoxin, and tumor necrosis factor in abdominal fluid and plasma in rats. Rosman C, Westerveld GJ, van Oeveren W, Kooi K, Bleichrodt RP. Eur Surg Res. 1996;28(5):351-60.

  163. Retransfusion of thoracic wound blood during heart surgery obscures biocompatibility of the extracorporeal circuit. de Haan J, Boonstra PW, Tabuchi N, van Oeveren W, Ebels T. J Thorac Cardiovasc Surg. 1996 Jan;111(1):272-5. No abstract available.

  164. Gelatin use impairs platelet adhesion during cardiac surgery. Tabuchi N, de Haan J, Gallandat Huet RC, Boonstra PW, van Oeveren W. Thromb Haemost. 1995 Dec;74(6):1447-51.

  165. Clinical performance of a high-efficiency rapid flow leucocyte removal filter for leucocyte depletion of heparinized cardiopulmonary bypass perfusate. Gu YJ, deVries AJ, Boonstra PW, van Oeveren W. Perfusion. 1995 Nov;10(6):425-30.

  166. Biomaterials for rotary blood pumps. van Oeveren W. Artif Organs. 1995 Jul;19(7):603-7. Review.

  167. Heparin-coated cardiopulmonary bypass circuit for use during lung transplantation. Gu YJ, van Oeveren W, Boonstra PW, de Boer WJ, Ebels T, Prop J. J Heart Lung Transplant. 1995 May-Jun;14(3):605-6. No abstract available.

  168. Retransfusion of suctioned blood during cardiopulmonary bypass impairs hemostasis. de Haan J, Boonstra PW, Monnink SH, Ebels T, van Oeveren W. Ann Thorac Surg. 1995 Apr;59(4):901-7.

  169. Procoagulant triggers during cardiopulmonary bypass. Tabuchi N, van Oeveren W. Blood. 1995 Mar 1;85(5):1405-6. No abstract available.

  170. Topical effect of aprotinin on the surgical wound in cardiac surgery. Tabuchi N, de Hoan J, van Oeveren W. J Thorac Cardiovasc Surg. 1995 Feb;109(2):399-400. No abstract available.

  171. Platelet function analysis after in vitro treatment with hemostasis-affecting components. Tigchelaar I, Monnink SH, Haan J, Tabuchi N, van Oeveren W. Semin Thromb Hemost. 1995;21 Suppl 2:71-6.

  172. Shear-induced pathway of platelet function in cardiac surgery. Tabuchi N, Tigchelaar I, van Oeveren W. Semin Thromb Hemost. 1995;21 Suppl 2:66-70.

  173. Activation of the plasma clotting, fibrinolytic, and kinin-kallikrein system in preterm infants with severe idiopathic respiratory distress syndrome. Brus F, van Oeveren W, Okken A, Oetomo SB. Pediatr Res. 1994 Nov;36(5):647-53.

  174. Blood compatibility of two different types of membrane oxygenator during cardiopulmonary bypass in infants. Gu YJ, Boonstra PW, Akkerman C, Mungroop H, Tigchelaar I, van Oeveren W. Int J Artif Organs. 1994 Oct;17(10):543-8.

  175. Monitoring of anticoagulation in aprotinin-treated patients during heart operation. Tabuchi N, Njo TL, Tigchelaar I, Huyzen RJ, Boonstra PW, van Oeveren W. Ann Thorac Surg. 1994 Sep;58(3):774-7.

  176. Activation of plasma components by leukocyte removal filters. Gu YJ, van Oeveren W. ASAIO J. 1994 Jul-Sep;40(3):M598-601.

  177. [Aprotinin and monitoring of heparin level during cardiopulmonary bypass: preliminary report]. Tabuchi N, van Oeveren W. Nihon Geka Gakkai Zasshi. 1994 Jul;95(7):479. Japanese. No abstract available.

  178. Systemic blood activation during and after autotransfusion. Schönberger JP, van Oeveren W, Bredée JJ, Everts PA, de Haan J, Wildevuur CR. Ann Thorac Surg. 1994 May;57(5):1256-62.

  179. Alternative perioperative anticoagulation monitoring during cardiopulmonary bypass in aprotinin-treated patients. Huyzen RJ, Harder MP, Huet RC, Boonstra PW, Brenken U, van Oeveren W. J Cardiothorac Vasc Anesth. 1994 Apr;8(2):153-6.

  180. Factor XII fragment and kallikrein generation in plasma during incubation with biomaterials. van der Kamp KW, van Oeveren W. J Biomed Mater Res. 1994 Mar;28(3):349-52.

  181. Heparin coating of an extracorporeal circuit partly improves hemostasis after cardiopulmonary bypass. Boonstra PW, Gu YJ, Akkerman C, Haan J, Huyzen R, van Oeveren W. J Thorac Cardiovasc Surg. 1994 Jan;107(1):289-92.

  182. Aprotinin effect on platelet function and clotting during cardiopulmonary bypass. Tabuchi N, De Haan J, Boonstra PW, Huet RC, van Oeveren W. Eur J Cardiothorac Surg. 1994;8(2):87-90.

  183. Tissue-type plasminogen activator and fibrin monomers synergistically cause platelet dysfunction during retransfusion of shed blood after cardiopulmonary bypass. de Haan J, Schönberger J, Haan J, van Oeveren W, Eijgelaar A. J Thorac Cardiovasc Surg. 1993 Dec;106(6):1017-23.

  184. Contact, coagulation and platelet interaction with heparin treated equipment during heart surgery. van der Kamp KW, van Oeveren W. Int J Artif Organs. 1993 Dec;16(12):836-42.

  185. Activation of fibrinolysis in the pericardial cavity during cardiopulmonary bypass. Tabuchi N, de Haan J, Boonstra PW, van Oeveren W. J Thorac Cardiovasc Surg. 1993 Nov;106(5):828-33.

  186. Rapid recovery of platelet function after cardiopulmonary bypass. Tabuchi N, de Haan J, van Oeveren W. Blood. 1993 Nov 1;82(9):2930-1. No abstract available.

  187. Preoperative therapy of low-dose aspirin in internal mammary artery bypass operations with and without low-dose aprotinin. Schönberger JP, Bredée JJ, van Oeveren W, van Zundert AA, Verkroost M, Terwoorst J, Bavinck JH, Berreklouw E, Wildevuur CR. J Thorac Cardiovasc Surg. 1993 Aug;106(2):262-7.

  188. Biocompatibility of leukocyte removal filters during leukocyte filtration of cardiopulmonary bypass perfusate. Gu YJ, Obster R, Haan J, Gallandat Huet RC, Eijgelaar A, van Oeveren W. Artif Organs. 1993 Jul;17(7):660-5.

  189. Blood activation during neonatal extracorporeal life support. Plötz FB, van Oeveren W, Bartlett RH, Wildevuur CR. J Thorac Cardiovasc Surg. 1993 May;105(5):823-32.

  190. Heparin-coated circuits reduce the inflammatory response to cardiopulmonary bypass. Gu YJ, van Oeveren W, Akkerman C, Boonstra PW, Huyzen RJ, Wildevuur CR. Ann Thorac Surg. 1993 Apr;55(4):917-22.

  191. Endotoxin release and tumor necrosis factor formation during cardiopulmonary bypass. Jansen NJ, van Oeveren W, Gu YJ, van Vliet MH, Eijsman L, Wildevuur CR. Ann Thorac Surg. 1992 Oct;54(4):744-7; discussion 747-8.

  192. A heparin-coated circuit reduces complement activation and the release of leukocyte inflammatory mediators during extracorporeal circulation in a rabbit. Plötz FB, van Oeveren W, Hultquist KA, Miller C, Bartlett RH, Wildevuur CR. Artif Organs. 1992 Aug;16(4):366-70.

  193. Anticoagulation policy during use of aprotinin in cardiopulmonary bypass. van Oeveren W, van Oeveren B, Wildevuur CR. J Thorac Cardiovasc Surg. 1992 Jul;104(1):210-1. No abstract available.

  194. Leukocyte activation with increased expression of CR3 receptors during cardiopulmonary bypass. Gu YJ, van Oeveren W, Boonstra PW, de Haan J, Wildevuur CR. Ann Thorac Surg. 1992 May;53(5):839-43.

  195. Biocompatibility of leukocyte removal filters during bedside leukocyte filtration of red cell concentrates. Gu YJ, Obster R, de Haan J, Huet RC, van Oeveren W. Transfus Sci. 1992;13(4):467-72. No abstract available.

  196. Inhibition by dexamethasone of the reperfusion phenomena in cardiopulmonary bypass. Jansen NJ, van Oeveren W, van den Broek L, Oudemans-van Straaten HM, Stoutenbeek CP, Joen MC, Roozendaal KJ, Eysman L, Wildevuur CR. J Thorac Cardiovasc Surg. 1991 Oct;102(4):515-25.

  197. Prophylactic administration of tranexamic acid preserves platelet numbers during extracorporeal circulation in rabbits. Plötz FB, van Oeveren W, Aloe LS, Riley MK, Hultquist KA, Bartlett RH, Wildevuur CR. ASAIO Trans. 1991 Jul-Sep;37(3):M416-7.

  198. Aprotinin reduces intraoperative and postoperative blood loss in membrane oxygenator cardiopulmonary bypass. Harder MP, Eijsman L, Roozendaal KJ, van Oeveren W, Wildevuur CR. Ann Thorac Surg. 1991 Jun;51(6):936-41.

  199. Methylprednisolone prophylaxis protects against endotoxin-induced death in rabbits. Jansen NJ, van Oeveren W, Hoiting BH, Wildevuur CR. Inflammation. 1991 Apr;15(2):91-101.

  200. Activation of plasma systems and blood cells by endotoxin in rabbits. Jansen NJ, van Oeveren W, Hoiting BH, Wildevuur CR. Inflammation. 1991 Apr;15(2):81-90.

  201. The role of different types of corticosteroids on the inflammatory mediators in cardiopulmonary bypass. Jansen NJ, van Oeveren W, van Vliet M, Stoutenbeek CP, Eysman L, Wildevuur CR. Eur J Cardiothorac Surg. 1991;5(4):211-7.

  202. Increased anticoagulation during cardiopulmonary bypass by aprotinin. de Smet AA, Joen MC, van Oeveren W, Roozendaal KJ, Harder MP, Eijsman L, Wildevuur CR. J Thorac Cardiovasc Surg. 1990 Oct;100(4):520-7.

  203. Aprotinin protects platelets against the initial effect of cardiopulmonary bypass. van Oeveren W, Harder MP, Roozendaal KJ, Eijsman L, Wildevuur CR. J Thorac Cardiovasc Surg. 1990 May;99(5):788-96; discussion 796-7.

  204. Biocompatibility of extracorporeal circuits in heart surgery. van Oeveren W, Wildevuur CR, Kazatchkine MD. Transfus Sci. 1990;11(1):5-33. Review. No abstract available.

  205. Methylprednisolone inhibits granulocytopenia induced by infusion of complement-activated serum but not of complement-activated plasma in rabbits. Jansen NJ, van Oeveren W, Wildevuur CR, Kazatchkine MD. Biomaterials. 1989 Nov;10(9):617-21.

  206. Platelet preservation during cardiopulmonary bypass with aprotinin. Wildevuur CR, Eijsman L, Roozendaal KJ, Harder MP, Chang M, van Oeveren W. Eur J Cardiothorac Surg. 1989;3(6):533-7; discussion 537-8.

  207. Platelet preservation by aprotinin during cardiopulmonary bypass. van Oeveren W, Eijsman L, Roozendaal KJ, Wildevuur CR. Lancet. 1988 Mar 19;1(8586):644. No abstract available.

  208. Effects of aprotinin on hemostatic mechanisms during cardiopulmonary bypass. van Oeveren W, Jansen NJ, Bidstrup BP, Royston D, Westaby S, Neuhof H, Wildevuur CR. Ann Thorac Surg. 1987 Dec;44(6):640-5.

  209. Bubble oxygenation and cardiotomy suction impair the host defense during cardiopulmonary bypass: a study in dogs. van Oeveren W, Dankert J, Wildevuur CR. Ann Thorac Surg. 1987 Nov;44(5):523-8.

  210. Prophylactic antibiotic treatment prevents infection after cardiopulmonary bypass: a study in dogs. van Oeveren W, Dankert J, Wildevuur W, Wildevuur CR. Ann Thorac Surg. 1987 May;43(5):544-9.

  211. Blood interactions in extracorporeal circulation: tests to evaluate the activation of proteins and formed blood elements. Wildevuur CR, van Oeveren W. Life Support Syst. 1987 Jan-Mar;5(1):85-91. No abstract available.

  212. Airborne contamination during cardiopulmonary bypass: the role of cardiotomy suction. van Oeveren W, Dankert J, Boonstra PW, Elstrodt JM, Wildevuur CR. Ann Thorac Surg. 1986 Apr;41(4):401-6.

  213. Deleterious effects of cardiopulmonary bypass. A prospective study of bubble versus membrane oxygenation. van Oeveren W, Kazatchkine MD, Descamps-Latscha B, Maillet F, Fischer E, Carpentier A, Wildevuur CR. J Thorac Cardiovasc Surg. 1985 Jun;89(6):888-99.

  214. Restoration of NADH oxidation with menaquinones and menaquinone analogues in membrane vesicles from the menaquinone-deficient Bacillus subtilis aroD. Bergsma J, Meihuizen KE, van Oeveren W, Konings WN. Eur J Biochem. 1982 Jul;125(3):651-7. No abstract available.